Why is Gilead Sciences stock down today? Price tests multi-week lows with reversal risk

Traders Union
All News
Financial News
Gilead Sciences drops 3.76% to $129.78

Highlights

Gilead Sciences secured FDA and European approvals for Trodelvy as first-line therapy in advanced triple negative breast cancer, expanding its commercial reach.
A new partnership with BBG Advanced Therapies will facilitate mobile deployment of Kite CAR T cell treatments in Texas, enhancing operational access.
GILD/USD trades under broad selling pressure with price near session lows; forecasted range is $125.39 to $134.17 amid volatility and mixed momentum signals.

Regulatory approvals contrast with ongoing price weakness amid operational wins

Gilead Sciences received FDA approval for Trodelvy as a first line treatment for advanced triple negative breast cancer, granting access to a new patient segment and expanding the company's addressable market. European regulators also approved Trodelvy in the same therapeutic setting, enabling commercial entry and potential uptake across eligible patients in the region. In addition, Gilead Sciences entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies throughout Texas, according to Finance Yahoo. These developments reflect a series of regulatory and operational advances, though price action has remained under broader selling pressure.

Multiple moving average breaches confirm bearish momentum despite mixed signals

GILD has fallen below its 20-day, 50-day, and 200-day moving averages, with immediate resistance identified at $133.38 according to the Ichimoku Kijun. Momentum signals present a mixed picture: the Moving Average Convergence Divergence (MACD) is Neutral, while the Average Directional Index (ADX) issues a Buy signal, pointing to trend strength without a clear direction. The Relative Strength Index (RSI), Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power are all in oversold territory, illustrating intense seller dominance. The Awesome Oscillator flags a Strong Sell, underscoring ongoing bearish momentum as price tests the lower end of the recent trading range.

Rangebound outlook favored as consolidation risk outweighs bullish breakout odds

Over the upcoming several trading sessions, GILD is anticipated to move within a range of $125.39 to $134.17. There is a 52% probability of price moving lower, with upside scenarios seen as less likely at 48%. As long as price holds above support and below resistance, a sideways consolidation is favored; however, a breakout above $133.38 could trigger a bullish move, while a drop below support would signal a continued retreat toward the lower boundary of the volatility band relative to current levels.

Anton Kharitonov, expert at Traders Union, notes that despite positive regulatory and partnership developments for Gilead Sciences, the technical picture remains pressured. He sees persistent selling, with price trading below all major moving averages and most indicators skewed to the downside. Resistance at $133.38 and oversold signals suggest intense seller control, making a sustained rebound unlikely without a confirmed breakout. "Base case remains sideways to lower as long as GILD stays below resistance — caution is warranted in the current trend."

Previously it was reported that Gilead Sciences faced persistent downside pressure despite recent regulatory wins, with analysts cautioning that bearish momentum dominated technical signals. With fresh approvals and partnerships now in play but mixed momentum indicators still prevailing, traders should monitor for a decisive move outside the current $125.39 to $134.17 range as the next directional cue.

Source of Data: GILD Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.